

West Virginia Pharmacy Services



Drug Utilization Review

1st Quarter 2026

Prepared by : **gainwell**



DUR Quarterly Overall Summary Report

Report Period from 01/01/2026 thru 03/31/2026

WVDRGS044

Categories	1st Qtr 2026	1st Qtr 2025	% Change
Total Paid Amount	\$257,199,858.76	\$238,852,525.75	7.68
Eligible Members	442,332	461,767	-4.21
Utilizing Eligibles	235,251	240,915	-2.35
Total # Prescriptions	1,976,087	1,971,026	0.26
Cost per Utilizing Member	\$1,093.30	\$991.44	10.27
Average # Prescriptions per Utilizer	8	8	0.00
Average Cost per Prescription	\$130.16	\$121.18	7.41
# Generic Prescriptions	1,742,469	1,727,904	0.84
% Generic Prescriptions	88	87	1.15
Total Cost - Generics	\$38,747,062.94	\$35,498,030.97	9.15
Average Generic Prescription Cost	\$22.24	\$20.54	8.24
Average Days Supply - Generics	32	31	3.23
# Brand Prescriptions	233,618	243,122	-3.91
% Brand Prescriptions	11.00	12.00	-8.33
Total Cost - Brand	\$218,452,795.82	\$203,354,494.78	7.42
Average Brand Prescription Cost	\$935.09	\$836.43	11.79
Average Days Supply - Brand	27	26	3.85
Rebates Collected	\$109,785,767.65	\$103,626,769.04	5.94



WVDRGS050

Top 25 Therapeutic Classes By Prescription Count

Report Period from 01/01/2026 thru 03/31/2026


Reporting Months (1st Quarter) 01/01/2026 - 03/31/2026

Rank	Therapeutic Class	Therapeutic Class Code	Prescription Count	% of Total Prescription Count	Amount Paid
1	ANTICONSULSANTS	H4B	94,669	4.70	\$4,907,637.08
2	OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	H3W	84,470	4.20	\$24,318,558.84
3	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	H2S	76,893	3.90	\$904,050.53
4	PROTON-PUMP INHIBITORS	D4J	62,758	3.10	\$955,584.30
5	ANTIHTAMINES - 2ND GENERATION	Z2Q	59,600	3.00	\$779,867.21
6	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB (STATINS)	M4D	52,330	2.60	\$607,442.06
7	BETA-ADRENERGIC AGENTS, INHALED, SHORT ACTING	B6W	51,123	2.60	\$1,728,083.52
8	NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE ANALGESICS	S2B	50,128	2.50	\$628,263.72
9	PENICILLIN ANTIBIOTICS	W1A	48,981	2.50	\$670,286.66
10	VITAMIN D PREPARATIONS	C6D	47,426	2.40	\$476,742.32
11	BETA-ADRENERGIC BLOCKING AGENTS	J7C	38,577	1.90	\$523,490.10
12	ANTIHTAMINES - 1ST GENERATION	Z2P	37,928	1.90	\$495,779.95
13	GLUCOCORTICIDS	P5A	37,913	1.90	\$1,108,917.05
14	ANTIEMETIC/ANTIVERTIGO AGENTS	H6J	37,793	1.90	\$565,650.97
15	ANTIPTYCHOTIC, ATYPICAL, DOPAMINE, SEROTONIN ANTAGNIST	H7T	36,552	1.80	\$6,539,925.48
16	SKELETAL MUSCLE RELAXANTS	H6H	32,897	1.60	\$418,439.46
17	TX FOR ATTENTION DEFICIT-HYPERACT (ADHD)/NARCOLEPSY	H2V	29,503	1.50	\$3,051,307.33
18	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	J5B	29,477	1.50	\$2,782,866.33
19	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	H7C	28,649	1.40	\$479,441.92
20	ANTI-ANXIETY DRUGS	H2F	27,934	1.40	\$374,659.48
21	SEROTONIN-2 ANTAGONIST/REUPTAKE INHIBITORS (SARIS)	H7E	26,731	1.30	\$309,792.47
22	ANTIHTERTENSIVES, ACE INHIBITORS	A4D	26,665	1.30	\$301,303.75
23	THYROID HORMONES	P3A	26,128	1.30	\$490,079.96
24	ANTIHTERTGLY, INCRETIN MIMETIC (GLP-1 RECEPTAGONIST)	C4I	25,790	1.30	\$24,126,441.72
25	NASAL ANTI-INFLAMMATORY STEROIDS	Q7P	25,265	1.30	\$704,932.57
Totals:			1,096,180	54.80	\$78,249,544.78

WV POS Quarterly Drug Class Review Top 12 by Rx Count

Reporting Period From: 01/01/2026 - 03/31/2026

Reporting Months (1st Quarter): 01/01/2026 - 03/31/2026



Amount Paid	
ANTICONVULSANTS	\$4,907,637.08
OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	\$24,318,558.84
SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	\$904,050.53
PROTON-PUMP INHIBITORS	\$955,584.30
ANTIHISTAMINES - 2ND GENERATION	\$779,867.21
ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(STATINS)	\$607,442.06
BETA-ADRENERGIC AGENTS, INHALED, SHORT ACTING	\$1,728,083.52
NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE ANALGESICS	\$628,263.72
PENICILLIN ANTIBIOTICS	\$670,286.66
VITAMIN D PREPARATIONS	\$476,742.32
BETA-ADRENERGIC BLOCKING AGENTS	\$523,490.10
ANTIHISTAMINES - 1ST GENERATION	\$495,779.95



WVDRGS029

Top 25 Therapeutic Classes by Amount Paid

Report Period from 01/01/2026 thru 03/31/2026


Reporting Months (1st Quarter): 1/1/2026-03/31/2026

Rank	Therapeutic Class	Therapeutic Class Codes	Amount Paid	% of Total Amount Paid	Prescription Count
1	OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	H3W	\$24,318,558.84	9.40	84,470
2	ANTIHYPERTENSIVE, INCRETIN MIMETIC (GLP-1 RECEPTOR AGONIST)	C4I	\$24,126,441.72	9.40	25,790
3	ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	S2J	\$16,257,596.40	6.30	1,968
4	CYSTIC FIBROSIS-CFTR POTENTIATOR-CORRECTOR COMBIN.	B0F	\$8,641,519.88	3.40	343
5	ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	V1Q	\$6,999,639.44	2.70	487
6	ANTIPRURITIC AGENTS, SYSTEMIC	L1A	\$6,547,563.53	2.50	617
7	ANTIPSYCHOTIC, ATYPICAL, DOPAMINE, SEROTONIN ANTAGONIST	H7T	\$6,539,925.48	2.50	36,552
8	ANTIHYPERTENSIVE-SODIUM/GLUCOCOTRANSPORTER (SGLT2) INH.	C4D	\$6,532,606.53	2.50	12,006
9	HEPATITIS C VIRUS- NS5A AND NS5B INHIBITOR COMB	W0E	\$6,311,565.73	2.40	505
10	ARV-NUCLEOSIDE, NUCLEOTIDE RTI, INTEGRASE INHIBITORS	W5X	\$5,408,475.55	2.10	1,201
11	INTERLEUKIN-4 (IL-4) RECEPTOR ALPHA ANTAGONIST, MAB	V4D	\$5,070,287.73	2.00	1,206
12	ANTIPSYCHOTIC-ATYPICAL, D3/D2 PARTIAL AG-5HT MIXED	H8W	\$4,972,024.18	1.90	3,407
13	ANTICONVULSANTS	H4B	\$4,907,637.08	1.90	94,669
14	INSULINS	C4G	\$4,839,248.06	1.90	21,067
15	BETA-ADRENERGIC AND GLUCOCORTICOID COMBO, INHALED	B63	\$4,331,344.05	1.70	18,746
16	DIABETIC SUPPLIES	Y9A	\$4,123,336.49	1.60	8,964
17	DIRECT FACTOR XA INHIBITORS	M9V	\$3,953,615.66	1.50	8,050
18	HEP C VIRUS-NS5B POLYMERASE AND NS5A INHIB. COMBO.	W0B	\$3,506,016.12	1.40	461
19	TX FOR ATTENTION DEFICIT-HYPERACT (ADHD)/NARCOLEPSY	H2V	\$3,051,307.33	1.20	29,503
20	ANTIMIGRAINE PREPARATIONS	H3F	\$2,873,238.42	1.10	11,982
21	ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED	H7X	\$2,855,526.77	1.10	14,063
22	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	J5B	\$2,782,866.33	1.10	29,477
23	HEMOPHILIA TREATMENT AGENTS, NON-FACTOR REPLACEMENT	M0P	\$2,651,745.76	1.00	67
24	AGENTS TO TREAT MULTIPLE SCLEROSIS	H0E	\$2,608,727.39	1.00	382
25	JANUS KINASE (JAK) INHIBITORS	Z2Z	\$2,325,408.08	0.90	360
Totals:			\$166,536,222.55	64.50	406,343

Top 12 Therapeutic Classes by Amount Paid

Reporting Months 1st Quarter: 1/1/2026-03/31/2026

Reporting Months (1st Quarter): 1/1/2026-03/31/2026



Prescriptions

OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	84,470
ANTIHYPERGLY, INCRETIN MIMETIC (GLP-1 RECEPTOR AGONIST)	25,790
ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	1,968
CYSTIC FIBROSIS-CFTR POTENTIATOR-CORRECTOR COMBIN.	343
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	487
ANTIPSORIATIC AGENTS, SYSTEMIC	617
ANTIPSYCHOTIC, ATYPICAL, DOPAMINE, SEROTONIN ANTAGONIST	36,552
ANTIHYPERGLYCEMIC-SODIUM/GLUCOCOTRANSPORT2 (SGLT2) INH	12,006
HEPATITIS C VIRUS- NS5A AND NS3/4A INHIBITOR COMB	505
ARV-NUCLEOSIDE, NUCLEOTIDE RTI, INTEGRASE INHIBITORS	1,201
INTERLEUKIN-4 (IL-4) RECEPTOR ALPHA ANTAGONIST, MAB	1,206
ANTIPSYCHOTIC-ATYPICAL, D3/D2 PARTIAL AG-5HT MIXED	3,407


Pharmacy Generic Utilization Summary by Amount Paid

Reporting Month 1st Quarter: 1/1/2026-03/31/2026

Reporting Months (1st Quarter): 1/1/2026-03/31/2026

Generic Utilization Summary

by Amount Paid



■	BNG	\$177,506,233	68.9 %
■	BWG	\$41,006,801	15.9 %
■	GEN	\$39,062,216	15.2 %
Total		\$257,575,250	100.0 %

BNG = Brand With no Generic Available


BWG = Brand Dispensed when Generic Available

GEN = Generic

Pharmacy Generic Utilization Summary By Number Of Prescriptions

Report Period from 01/01/2026 thru 03/31/2026

Reporting Months (1st Quarter): 1/1/2026-03/31/2026



BNG = Brand With no Generic Available


BWG = Brand Dispensed when Generic Available

GEN = Generic

Pharmacy DUR Savings - QUARTERLY

Report Period from 01/01/2026 thru 03/31/2026

Reporting Months (1st Quarter) : 1/1/2026 - 3/31/2026



Code	Description	Amount Saved	% of Savings
DD	Drug-Drug Interactions	\$1,296,975.74	2.00
ER	Early Refill	\$31,302,963.94	59.00
HD	High Dose	\$953,111.95	2.00
ID	Ingredient Duplication	\$1,924,811.14	4.00
LR	Late Refill	\$0.00	0.00
PG	Pregnancy Precaution	\$357,416.98	1.00
TD	Therapeutic Duplication	\$16,919,157.01	32.00
Totals:		\$52,754,436.76	100.00